Topic Archives: ViewRay (VRAY)

Identifying Manward’s teased “$5 Cancer Killer That’s Headed to $50”

Andrew Snyder has been on the editorial team of a bunch of different Agora-affiliated newsletters over the years, and is now helming his own little offshoot called Manward Press — a publishing imprint that aims to helm men reach “true fulfillment” by focusing on “Liberty, Know-how and connections” … though, of course, to sell newsletters […]

Identifying Lashmet’s December 31, 2017 medical breakthrough: “Radical treatment that could treat 1 in 2 of all cancer patients”

Lots and lots and lots of you have been asking me about the big “cancer presentation” that the Stansberry folks made last night, which apparently was a combination of Dr. David Eifrig’s medical advice and forecasting and Dave Lashmet’s hinting about his “medical breakthrough” stock… so let’s get to it. I did not watch or […]

Comments

  • Avatar

    Apart from drug therapy, it might be profitable to look into a new technique in radiation treatments - two players Elekt...

  • Travis Johnson, Stock Gumshoe

    Oh, and yes, it turns out that long Elekta/short ViewRay would have been the right call -- VRAY is down 23% at the momen...

  • Avatar

    I joined the same webinar and took careful notes. It was mentioned that the stock in question was in an uptrend. So, I a...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch